SeraGene Therapeutics

Cover Block

Name	SeraGene Therapeutics
Tagline	RNA-based nanomedicine therapies for blood coagulation disorders
Headquarters	Vancouver, Canada
Founded	2022
Stage	Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed

Links

• Website: https://www.seragenetx.com/
• LinkedIn: https://ca.linkedin.com/company/seragene-tx

What an Investor Needs First

SeraGene Therapeutics is a preclinical biotech developing RNA-based nanomedicines to treat blood coagulation disorders, backed by a strategic, disease-focused venture philanthropy fund [NBDF, Feb 2026]. The company originated as a spinout from the Nanomedicines Innovation Network (NMIN) and the Versiti Blood Research Institute, channeling academic research on clotting biology and lipid nanoparticle (LNP) delivery into a commercial pipeline [Perplexity Sonar Pro Brief]. Its core platform uses proprietary, liver-targeted siRNA delivered via LNPs to precisely modulate the expression of clotting proteins, aiming to create long-acting prophylactic therapies for conditions like hemophilia and thrombosis [NBDF, Feb 2026].

SeraGene is in its seed stage, having secured a strategic investment from Pathway to Cures, the venture arm of the National Bleeding Disorders Foundation, in November 2025 [Crunchbase]. The company has progressed through accelerators including adMare BioInnovations and Creative Destruction Lab [adMare BioInnovations].

Data Accuracy: YELLOW -- Core technology and recent funding confirmed by primary sources; team details and pipeline specifics are partially corroborated.

Inside the Company

SeraGene Therapeutics is a preclinical biotechnology company founded in 2022, operating as a spinout from the Versiti Blood Research Institute in Wisconsin and the University of British Columbia's Center for Blood Research [NBDF, Feb 2026]. The company is headquartered in Vancouver, Canada, and was formed with the backing of the Nanomedicines Innovation Network [NMIN, Oct 2024].

Its early development has been marked by participation in Canadian life sciences accelerators, including adMare BioInnovations and Creative Destruction Lab [adMare BioInnovations]. The company secured its first disclosed equity investment in November 2025, a strategic seed round led by the venture philanthropy fund Pathway to Cures [Crunchbase].

SeraGene was named a Company to Watch at the 2024 Life Sciences BC Awards, won a prize at Sweet Pharma Day 2024, and was a finalist in the 2025 Lilly Grand Challenge [NBDF, Feb 2026].

Data Accuracy: YELLOW -- Company origin and accelerator affiliations are confirmed by multiple sources; funding round is confirmed by Crunchbase.

Under the Hood

SeraGene Therapeutics is building a platform for long-acting RNA therapies, aiming to shift the treatment paradigm for coagulation disorders from reactive to prophylactic. The company’s core technology involves delivering proprietary small interfering RNA (siRNA) agents to liver cells using targeted lipid nanoparticles (LNPs), a method designed to precisely modulate the expression of clotting proteins [NBDF, Feb 2026].

The platform supports a portfolio of eight patented assets, ranging from discovery to late preclinical stages, with preclinical data generated in large-animal disease models [Perplexity Sonar Pro Brief]. The flagship program, SG-001, is a universal siRNA-based hemostatic agent intended for monthly dosing to treat rare bleeding disorders; its mechanism targets mRNA to suppress plasminogen to stabilize blood clots [Perplexity Sonar Pro Brief]. A second mechanistic approach aims to enhance the expression of specific genes required for coagulation.

SeraGene’s development pipeline is organized around three thematic areas: prophylactic therapies for rare bleeding disorders, enhanced transfusable platelets for platelet dysfunction, and prophylactic therapies for thrombotic disorders [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core technology and pipeline themes are described in a primary source profile [NBDF, Feb 2026]; asset count and mechanistic details are from a single aggregated research brief.

Market Research

SeraGene's focus on RNA-based nanomedicines for coagulation disorders sits within a broader therapeutic shift. The global market for hemophilia treatments is projected to reach approximately $20,000M by 2030 [Grand View Research, 2024]. The broader RNA therapeutics market is forecast to grow from around $6,000M in 2023 to over $25,000M by 2030 [Precedence Research, 2024].

Metric	Value
Hemophilia Treatment Market (2030)	$20,000M
RNA Therapeutics Market (2030)	$25,000M

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to SeraGene's pipeline.

Competition and Substitutes

SeraGene is positioning itself in a niche where RNA-based therapies intersect with hematology. The competitive map for coagulation disorders is stratified by therapeutic modality. Incumbents include recombinant clotting factor concentrates (Takeda, Bayer, Sanofi) and non-factor replacement therapies (Roche/Genentech). Newer genetic therapies, such as AAV gene therapies from BioMarin and Pfizer/Spark Therapeutics, offer potential functional cures but carry high costs and manufacturing complexity. SeraGene's proposed edge lies in occupying a middle ground: aiming for the durable, prophylactic effect of a genetic therapy but using a transient, repeatable siRNA/LNP platform [NBDF, Feb 2026].

Data Accuracy: YELLOW -- Competitive context is inferred from therapeutic landscape analysis; specific competitor claims and SeraGene's differentiation are sourced from NBDF and ecosystem materials.

Opportunity

SeraGene aims to establish a category-defining platform for long-acting, liver-targeted RNA interference in hemostasis. The company's aim is a validated delivery system for modulating clotting proteins applicable across a spectrum of bleeding and thrombotic conditions [NBDF, Feb 2026].

Scenario	What happens	Catalyst	Why it's plausible
Niche-to-Broad Leader	SG-001 gains orphan drug designation and approval for a rare bleeding disorder.	Successful completion of a Phase 1/2 clinical trial.	SG-001 is a universal siRNA-based hemostatic agent intended for monthly dosing [Perplexity Sonar Pro Brief].
Platform Licensing to Big Pharma	A major pharmaceutical company licenses SeraGene's LNP delivery platform.	Publication of compelling large-animal model data for a second pipeline asset.	Lipid nanoparticles have proven clinical success in other RNA therapeutic areas [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Opportunity analysis is based on cited company claims and ecosystem validations; market size and comparables are inferred from the broader therapeutic category.